Literature DB >> 11036022

In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains.

S Rochon-Edouard1, M Pestel-Caron, J F Lemeland, F Caron.   

Abstract

Several studies have previously reported synergistic effects between vancomycin and a given beta-lactam or a given aminoglycoside against methicillin-resistant Staphylococcus aureus (MRSA) strains. The aim of our study was to exhaustively compare the effects of different combinations of a beta-lactam, vancomycin, and/or an aminoglycoside against 32 clinical MRSA strains with different aminoglycoside susceptibility patterns. The effects of 26 different beta-lactam-vancomycin and 8 different aminoglycoside-vancomycin combinations were first studied using a disk diffusion screening method. The best interactions with vancomycin were observed with either imipenem, cefazolin, or netilmicin. By checkerboard studies, imipenem-vancomycin and cefazolin-vancomycin each provided a synergistic bacteriostatic effect against 22 strains; the mean fractional inhibitory concentration (FIC) indexes were 0.35 and 0.46 for imipenem-vancomycin and cefazolin-vancomycin, respectively. The vancomycin-netilmicin combination provided an indifferent effect against all of the 32 strains tested; the mean of FIC index was 1. 096. The mean concentrations of imipenem, cefazolin, netilmicin, and vancomycin at which FIC indexes were calculated were clinically achievable. Killing experiments were then performed using imipenem, cefazolin, netilmicin, and vancomycin at one-half of the MIC, alone and in different combinations, against 10 strains. The vancomycin-netilmicin regimen was rarely bactericidal, even against strains susceptible to netilmicin. The imipenem-vancomycin and cefazolin-vancomycin combinations were strongly bactericidal against six and five strains, respectively. The addition of netilmicin markedly enhanced the killing activity of the combination of cefazolin or imipenem plus vancomycin, but only for the MRSA strains against which the beta-lactam-vancomycin combinations had no bactericidal effect. It is noteworthy that the latter strains were both susceptible to netilmicin and heterogeneously resistant to methicillin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036022      PMCID: PMC101602          DOI: 10.1128/AAC.44.11.3055-3060.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  K Totsuka; M Shiseki; K Kikuchi; Y Matsui
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

Review 2.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.

Authors:  M Michel; L Gutmann
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

3.  An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

4.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 5.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

6.  The antibacterial activity of meropenem in combination with gentamicin or vancomycin.

Authors:  R Wise; J P Ashby; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.

Authors:  S L Kang; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

8.  Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.

Authors:  E Hershberger; J R Aeschlimann; T Moldovan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

9.  The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.

Authors:  G Seibert; D Isert; N Klesel; M Limbert; A Markus; E Schrinner
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

10.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

View more
  16 in total

1.  In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

4.  Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.

Authors:  Vincent H Tam; Amy N Schilling; Russell E Lewis; David A Melnick; Adam N Boucher
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.

Authors:  Shigeharu Oie; Yumi Fukui; Masaya Yamamoto; Yuki Masuda; Akira Kamiya
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

Review 6.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Rong-mei Liang; Xiao-lan Yong; Yu-qin Duan; Yong-hong Tan; Ping Zeng; Zi-ying Zhou; Yan Jiang; Shi-hua Wang; Yun-ping Jiang; Xiao-chun Huang; Zhao-hui Dong; Ting-ting Hu; Hui-qing Shi; Nan Li
Journal:  World J Microbiol Biotechnol       Date:  2014-08-10       Impact factor: 3.312

8.  Rapid depletion of free vancomycin in medium in the presence of beta-lactam antibiotics and growth restoration in Staphylococcus aureus strains with beta-lactam-induced vancomycin resistance.

Authors:  Chie Yanagisawa; Hideaki Hanaki; Hidehito Matsui; Shinsuke Ikeda; Taiji Nakae; Keisuke Sunakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

9.  Synergy of β-Lactams with Vancomycin against Methicillin-Resistant Staphylococcus aureus: Correlation of Disk Diffusion and Checkerboard Methods.

Authors:  Cheng Len Sy; Tsi-Shu Huang; Chii Shiang Chen; Yao-Shen Chen; Hung-Chin Tsai; Shue-Renn Wann; Kuan-Sheng Wu; Jui-Kuang Chen; Susan Shin-Jung Lee; Yung-Ching Liu
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

10.  Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.

Authors:  Thomas J Dilworth; Jora Sliwinski; Keenan Ryan; Monique Dodd; Renée-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.